Short Communication: Early Changes in Parathyroid Hormone Concentrations in HIV-Infected Patients Initiating Antiretroviral Therapy with Tenofovir
- 1 March 2012
- journal article
- research article
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 28 (3) , 242-246
Abstract
Initiation of combined antiretroviral therapy (cART) is associated with bone loss, which may be more intense with regimens including tenofovir. The underlying mechanisms are not well understood. Cross-sectional data have linked tenofovir with higher parathyroid hormone (PTH) concentrations in patients with vitamin D deficiency. We performed a longitudinal study with a 48-week follow-up to evaluate sequential changes in PTH and 25-hydroxyvitamin D [25(OH)D] levels in patients starting cART with either tenofovir/emtricitabine or abacavir/lamivudine. Fifty-seven patients were included, 31 initiating tenofovir/emtricitabine and 26 initiating abacavir/lamivudine. Median PTH levels turned out to be significantly higher among tenofovir/emtricitabine users at week 4 (p=0.01), week 24 (p=0.008), and week 36 (p=0.02), and were above the upper limits of normal values (ULN) at weeks 24, 36, and 48 only in patients receiving tenofovir/emtricitabine. 25(OH)D, serum and urine calcium and phosphate, and renal-tubular maximum reabsorption of phosphate to the glomerular filtration rate (TmP/GFR) levels did not differ between the two treatment arms over the study period. Among tenofovir/emtricitabine users, median (interquartile range) PTH concentrations were significantly higher in patients with suboptimal 25(OH)D levels (p=0.05] and week 48 [67.5 (59.6–86.0) ng/liter vs. 41.9 (37.3–68.8) ng/liter, p=0.03]. A multivariable logistic regression model showed that tenofovir/emtricitabine use was an independent predictor of high PTH levels (≥53 ng/liter). Starting cART with tenofovir regimens is associated with an elevation in PTH plasma concentrations soon after introducing the drug. Suboptimal baseline 25(OH)D levels increase the risk of developing secondary hyperparathyroidism among tenofovir users.Keywords
This publication has 11 references indexed in Scilit:
- High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort studyAIDS, 2010
- Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT StudyClinical Infectious Diseases, 2010
- Tenofovir-Linked Hyperparathyroidism Is Independently Associated With the Presence of Vitamin D DeficiencyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Short Communication: Inadequate Vitamin D Exacerbates Parathyroid Hormone Elevations in Tenofovir UsersAIDS Research and Human Retroviruses, 2010
- High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patientsAIDS, 2010
- Simplification of Antiretroviral Therapy with Tenofovir‐Emtricitabine or Abacavir‐Lamivudine: A Randomized, 96‐Week TrialClinical Infectious Diseases, 2009
- Tenofovir‐associated renal and bone toxicityHIV Medicine, 2009
- Tenofovir-Associated Fanconi Syndrome: Review of the FDA Adverse Event Reporting SystemAIDS Patient Care and STDs, 2008
- Vitamin D DeficiencyNew England Journal of Medicine, 2007
- Renal Tubular Dysfunction Associated With Tenofovir TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2004